Trials / Completed
CompletedNCT03866460
Determining Whether Intra-Arterial Carboplatin Causes Hearing Loss in Children
Determination of Hearing Status in Children Receiving Intra-Arterial Carboplatin for Intraocular Retinoblastoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 3 Months – 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out how often hearing loss occurs in patients with retinoblastoma after receiving treatment with intra-arterial carboplatin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Distortion product otoacoustic emission measurement (DPOAE) | Hearing will be measured at baseline and 3-9 months after completion of treatment with IA carboplatin chemotherapy. |
Timeline
- Start date
- 2019-03-06
- Primary completion
- 2024-11-04
- Completion
- 2024-11-04
- First posted
- 2019-03-07
- Last updated
- 2024-11-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03866460. Inclusion in this directory is not an endorsement.